Back to Journals » Clinical Ophthalmology » Volume 3

Central corneal thickness in subjects with glaucoma and in normal individuals (with or without pseudoexfoliation syndrome)

Authors Kitsoso G, Gartzios C, Asproudis I, Bagli E

Published 30 September 2009 Volume 2009:3 Pages 537—542


Review by Single anonymous peer review

Peer reviewer comments 2

Georgios Kitsos, Christos Gartzios, Ioannis Asproudis, Eleni Bagli

Ophthalmology Department, University of Ioannina, Ioannina, Greece

Objective: The evaluation of central corneal thickness (CCT) in subjects with pesudoexfoliation glaucoma (PEXG), primary open-angle glaucoma (POAG), and in normotensive individuals with or without pseudoexfoliation syndrome (PXS). Study design/patients and methods: CCT was evaluated with ultrasound pachymetry in a total of 179 individuals: 32 had bilateral PEXG, 55 had bilateral POAG, 35 had PXS, and 57 were healthy individuals without PXS.

Results: CCT in PEXG eyes (526.00 ± 34.30 µm) was significantly thinner compared to POAG eyes (549.36 ± 39.3 µm) (P = 0.027) and normal control eyes with (550.64 ± 39.0 µm) or without PXS (547.36 ± 33.1 µm), (P = 0.039 and 0.048 respectively). No statistically significant difference was found comparing CCT values of POAG eyes to control group eyes.

Conclusion: The evaluation of CCT is necessary in all patients with glaucoma and especially in those with PEXG due to the thinner cornea and the risk of underestimation of intraocular pressure.

Keywords: CCT, pesudoexfoliation syndrome, glaucoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.